Skip to content
Inciteful Med
Resources About us Ask a Question

What Does MRD Negative Mean in Multiple Myeloma?

Published: | Updated:

In multiple myeloma, being MRD negative means highly sensitive bone marrow tests cannot detect any cancer cells. While not officially a cure, it is the deepest possible remission and strongly predicts a longer period without the disease returning. Maintaining current therapy is usually advised.

Key Takeaways

  • • Being MRD negative means highly sensitive tests cannot detect a single multiple myeloma cell among up to a million healthy bone marrow cells.
  • • While it is the deepest level of remission, it is not officially a cure because microscopic cells can hide elsewhere in the body.
  • • Achieving MRD negativity is the strongest predictor of a longer remission and better overall survival.
  • • Confirming MRD negativity currently requires a bone marrow biopsy using advanced DNA or cell-scanning technology.
  • • Doctors typically recommend continuing maintenance therapy even after achieving an MRD negative result to keep the disease suppressed.

Hearing that your recent bone marrow biopsy was “MRD negative” is excellent news, but it does not officially mean your multiple myeloma is cured. MRD stands for Minimal Residual Disease, which refers to the microscopic number of cancer cells that can remain in your body after treatment. Being “MRD negative” means that your treatment has been so successful that highly sensitive tests cannot find even a single myeloma cell among up to a million healthy bone marrow cells [1][2]. While it is considered the deepest possible level of remission and strongly predicts a longer period without the disease returning, doctors avoid using the word “cure” because there is still a chance that undetectable cells are hiding elsewhere in the body [3][4][5].

What is Minimal Residual Disease (MRD)?

Historically, doctors evaluated treatment success using standard blood and urine tests to look for a remission. However, even when a patient achieved a complete response (meaning no cancer proteins were found using conventional tests), small amounts of myeloma cells could still be left behind, eventually causing a relapse [1][2].

MRD testing was developed to look much deeper. Using advanced technologies, modern MRD tests evaluate the bone marrow at a microscopic level, significantly surpassing the limits of older tests [6][7]. An MRD test usually looks for one myeloma cell among 100,000 healthy cells (a sensitivity of 10−510^{-5}) or even one cell in 1,000,000 healthy cells (10−610^{-6}) [6][8].

How is MRD Tested?

Currently, confirming MRD negativity requires a bone marrow biopsy [9][10]. The standard, highly sensitive techniques used to find these hidden cells are:

  • Next-Generation Sequencing (NGS): Analyzes the DNA of the cells in your bone marrow to look for the specific genetic signature of your myeloma [9][7]. This test typically requires a baseline bone marrow sample from when you were first diagnosed so the lab knows exactly what unique genetic markers to look for.
  • Next-Generation Flow Cytometry (NGF): Uses lasers to scan cells rapidly and identify the abnormal proteins on the surface of myeloma cells [9][10].

Both methods are incredibly accurate, and research shows no significant difference between them in successfully detecting minimal residual disease [11][6]. However, because bone marrow biopsies are invasive, researchers are exploring less invasive ways to track MRD in the future, such as through liquid biopsies (advanced blood tests looking for tumor DNA) and mass spectrometry [12][13][14]. Note that these blood-based methods are still being researched and are not yet available to replace routine bone marrow biopsies.

Why MRD Negative Isn’t Officially a “Cure”

It is completely natural to want to hear the word “cure” when you reach this profound level of remission. However, an MRD negative result is a snapshot of one specific sample from your bone marrow at a single point in time. There are two main reasons this does not guarantee a permanent cure:

  1. Technological Limits: Even the best tests have a limit. If you have one cancer cell per two million healthy cells, an MRD test looking at one million cells might miss it [1][5].
  2. Sanctuary Sites: Myeloma cells can occasionally hide in other parts of the body (known as extramedullary disease) or different areas of the bone marrow that were not captured by the biopsy needle [1][8]. Because of this, doctors often use advanced imaging, like PET-CT or MRI scans, alongside bone marrow tests to ensure no cancer is hiding outside the bone marrow.

The Prognostic Power of Being MRD Negative

Even though it is not called a cure, achieving MRD negativity is widely considered the strongest predictor of a good outcome in multiple myeloma [2][15][1].

  • Longer Remissions: Patients who reach MRD negativity consistently have significantly longer progression-free survival (time lived without the disease getting worse) and overall survival compared to those who are MRD positive [15][16][17].
  • Offsetting High Risk: This improved outcome is seen across the board. While it does not completely erase the dangers of high-risk genetic features, reaching MRD negativity dramatically improves outcomes and helps offset that risk, bringing prognosis closer to those with standard-risk disease [4][5][18].
  • Sustained Negativity: Doctors are increasingly focusing on sustained MRD negativity, which means staying MRD negative on multiple tests over time (such as 6 or 12 months apart). Achieving sustained MRD negativity provides even greater confidence in a long-term remission [19][1].

What This Means For Your Treatment Right Now

A common question after receiving an MRD-negative result is: “Since no cancer was found, can I stop taking my maintenance chemotherapy?”

While clinical trials are actively studying whether some patients with sustained MRD negativity can safely stop or reduce their treatment [20][21], stopping treatment is not yet the standard of care. Currently, doctors usually recommend continuing your maintenance therapy (like daily pills) even after achieving MRD negativity. This ongoing treatment is often what helps keep the disease suppressed and maintains that profound remission [19][1]. Always discuss any changes to your treatment directly with your care team.

Frequently Asked Questions

Is multiple myeloma cured if I am MRD negative?
Being MRD negative is excellent news and indicates the deepest level of remission, but it is not officially considered a cure. Microscopic cancer cells may still be hiding in other parts of the body or fall below the detection limit of the highly sensitive test.
How is an MRD test performed for multiple myeloma?
Confirming MRD negativity currently requires a bone marrow biopsy. The sample is analyzed using highly sensitive techniques like Next-Generation Sequencing or Next-Generation Flow Cytometry to look for hidden myeloma cells among hundreds of thousands of healthy cells.
Can I stop my maintenance therapy if my MRD test is negative?
Even with an MRD negative result, doctors usually recommend continuing your maintenance therapy. This ongoing treatment is important to keep the disease suppressed and maintain your deep remission. You should always discuss treatment changes with your care team.
Do I need other tests besides a bone marrow biopsy to confirm my remission?
Because a bone marrow biopsy only checks one specific spot, doctors often use advanced imaging like PET-CT or MRI scans alongside bone marrow tests. This helps ensure that no multiple myeloma cells are hiding outside the bone marrow.
What does sustained MRD negativity mean?
Sustained MRD negativity means that you have achieved an MRD negative result on multiple tests over a period of time, such as six or twelve months apart. This provides even greater confidence in a long-term remission.

Questions for Your Doctor

  • • What was the specific sensitivity threshold of my MRD test (e.g., 1 in 100,000 or 1 in 1,000,000 cells)?
  • • Do we plan to repeat this MRD test in the future to check for sustained MRD negativity?
  • • Since the bone marrow biopsy only looks at one site, should we perform an imaging study like a PET-CT to ensure there is no disease hiding elsewhere?
  • • How does my MRD negative status affect our plans for my current maintenance therapy?
  • • Was a baseline genetic sample from my initial diagnosis used for this test, and does the lab have everything they need for future monitoring?

Questions for You

  • • How does the news of being MRD negative change how I feel about my daily life and future plans?
  • • What are my current personal priorities now that my myeloma is in a deep remission?
  • • Am I comfortable with the level of monitoring and maintenance therapy my care team has proposed going forward?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.

    Schmitz A, Brøndum RF, Johnsen HE, et al.

    BMC cancer 2022; (22(1)):147 doi:10.1186/s12885-022-09184-1.

    PMID: 35123422
  2. 2

    New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response.

    Mohan Lal B, Kumar SK

    Current hematologic malignancy reports 2026; (21(1)):4 doi:10.1007/s11899-026-00771-8.

    PMID: 41689620
  3. 3

    Minimal residual disease in multiple myeloma: current status.

    Ding H, Xu J, Lin Z, et al.

    Biomarker research 2021; (9(1)):75 doi:10.1186/s40364-021-00328-2.

    PMID: 34649622
  4. 4

    Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.

    Paiva B, Puig N, Cedena MT, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(8)):784-792 doi:10.1200/JCO.19.01231.

    PMID: 31770060
  5. 5

    Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time?

    Mina R, Bonello F, Oliva S

    Cancer journal (Sudbury, Mass.) 2021; (27(3)):247-255 doi:10.1097/PPO.0000000000000519.

    PMID: 34549914
  6. 6

    Moving Toward a Cure for Myeloma.

    Mateos MV, Nooka AK, Larson SM

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2022; (42()):1-12 doi:10.1200/EDBK_349603.

    PMID: 35623025
  7. 7

    MRD in multiple myeloma: more questions than answers?

    Moreau P, Zamagni E

    Blood cancer journal 2017; (7(12)):639 doi:10.1038/s41408-017-0028-5.

    PMID: 29209089
  8. 8

    Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.

    Kim HY, Yoo IY, Lim DJ, et al.

    Annals of laboratory medicine 2022; (42(5)):558-565 doi:10.3343/alm.2022.42.5.558.

    PMID: 35470273
  9. 9

    Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.

    Gozzetti A, Bocchia M

    Reviews on recent clinical trials 2022; (17(1)):9-10 doi:10.2174/1574887116666211123092915.

    PMID: 34814822
  10. 10

    Advancing MRD Detection in Multiple Myeloma: Technologies, Applications, and Future Perspectives.

    Chen B, Pan Q, Dong Y

    American journal of clinical oncology 2025; (48(7)):376-380 doi:10.1097/COC.0000000000001197.

    PMID: 40214184
  11. 11

    [Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].

    Wang QQ, Yao L, Zhu MQ, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2023; (44(4)):328-332 doi:10.3760/cma.j.issn.0253-2727.2023.04.011.

    PMID: 37357003
  12. 12

    Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.

    Kubicki T, Dytfeld D, Barnidge D, et al.

    Blood 2024; (144(9)):955-963 doi:10.1182/blood.2024024041.

    PMID: 38713888
  13. 13

    Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).

    Fan H, Wang B, Shi L, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(6)):1131-1142 doi:10.1158/1078-0432.CCR-23-2767.

    PMID: 38170583
  14. 14

    Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma.

    Gozzetti A, Bocchia M

    Oncology research 2023; (31(3)):271-274 doi:10.32604/or.2023.028668.

    PMID: 37305387
  15. 15

    Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

    Landgren O, Devlin S, Boulad M, Mailankody S

    Bone marrow transplantation 2016; (51(12)):1565-1568 doi:10.1038/bmt.2016.222.

    PMID: 27595280
  16. 16

    Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.

    de Tute RM, Pawlyn C, Cairns DA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(25)):2889-2900 doi:10.1200/JCO.21.02228.

    PMID: 35377708
  17. 17

    Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.

    Landgren O, Hultcrantz M, Diamond B, et al.

    JAMA oncology 2021; (7(6)):862-868 doi:10.1001/jamaoncol.2021.0611.

    PMID: 33856405
  18. 18

    Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

    Moreau P, Attal M, Hulin C, et al.

    Lancet (London, England) 2019; (394(10192)):29-38 doi:10.1016/S0140-6736(19)31240-1.

    PMID: 31171419
  19. 19

    Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.

    Diamond B, Korde N, Lesokhin AM, et al.

    The Lancet. Haematology 2021; (8(6)):e422-e432 doi:10.1016/S2352-3026(21)00130-7.

    PMID: 34048681
  20. 20

    Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?

    Scott SD, Fletcher M, Whitehouse H, et al.

    Cytometry. Part B, Clinical cytometry 2019; (96(3)):201-208 doi:10.1002/cyto.b.21754.

    PMID: 30565840
  21. 21

    Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

    Perrot A, Lauwers-Cances V, Corre J, et al.

    Blood 2018; (132(23)):2456-2464 doi:10.1182/blood-2018-06-858613.

    PMID: 30249784

This page explains MRD testing in multiple myeloma for educational purposes only. Always consult your oncologist or hematologist to interpret your specific bone marrow biopsy results and make treatment decisions.

Stay up to date

Get notified when new research about Multiple Myeloma is published.

No spam. Unsubscribe anytime.